The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2023 | An update on MANIFEST: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the findings of the MANIFEST study (NCT02158858) evaluating the efficacy and safety of pelabresib, an investigational BET inhibitor in patients with myelofibrosis (MF) and essential thrombocythemia (ET). The study is composed of four arms: patient receiving pelabresib monotherapy, pelabresib as an add-on treatment to ruxolitinib in patients with a suboptimal response to ruxolitinib, pelabresib plus ruxolitinib in JAK inhibitor-naive patients, and pelabresib in patients with ET who are hydroxyurea-resistant. The combination of pelabresib and ruxolitinib achieved promising results in JAK inhibitor-naive patients in terms of spleen and symptom responses, bone marrow fibrosis reduction, and JAK2 variant allele frequency (VAF) reduction. In addition, patients with ET also experienced high hematologic and symptom responses. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
